Lexicon Pharmaceuticals to Present Sotagliflozin Data at ACC Annual Meeting

Lexicon Pharmaceuticals will present three studies on sotagliflozin at the American College of Cardiology Annual Meeting. The studies focus on sotagliflozin's effectiveness in reducing heart failure and major adverse cardiovascular events, as well as its potential benefits in people with type 2 diabetes and chronic kidney disease. The data also suggest that sotagliflozin may improve health-related quality of life and physical limitation in people with heart failure and preserved ejection fraction.